Hesperidin and icaritin exhibit potential in suppressing PD-L1 expression in various cancer cells, including estrogen-dependent triple-negative breast cancer and androgen-dependent prostate cancer cells. The gene discussed is CD274; the disease is triple-negative breast carcinoma.